Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Analysts

Compass Therapeutics, Inc. (NASDAQ:CMPX) has been given an average rating of “Moderate Buy” by the fifteen analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, thirteen have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $13.00.

A number of analysts have recently issued reports on the company. Wall Street Zen raised Compass Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 16th. Citizens Jmp set a $10.00 price objective on Compass Therapeutics in a report on Wednesday, December 3rd. Citigroup began coverage on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. They set an “outperform” rating on the stock. Canaccord Genuity Group set a $13.00 target price on shares of Compass Therapeutics in a report on Wednesday, February 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Wednesday, January 21st.

Compass Therapeutics Trading Up 0.7%

Shares of Compass Therapeutics stock opened at $5.45 on Wednesday. Compass Therapeutics has a twelve month low of $1.33 and a twelve month high of $6.88. The firm has a market capitalization of $981.49 million, a PE ratio of -12.67 and a beta of 1.48. The firm’s 50-day moving average price is $5.93 and its 200 day moving average price is $4.93.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. On average, sell-side analysts predict that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CMPX. Caitong International Asset Management Co. Ltd acquired a new position in shares of Compass Therapeutics during the 4th quarter worth approximately $132,000. Seven Fleet Capital Management LP acquired a new stake in shares of Compass Therapeutics in the fourth quarter valued at approximately $3,054,000. Invesco Ltd. increased its holdings in shares of Compass Therapeutics by 5.3% in the fourth quarter. Invesco Ltd. now owns 63,901 shares of the company’s stock valued at $343,000 after purchasing an additional 3,245 shares during the last quarter. XTX Topco Ltd lifted its position in Compass Therapeutics by 582.2% during the fourth quarter. XTX Topco Ltd now owns 115,634 shares of the company’s stock worth $621,000 after buying an additional 98,684 shares in the last quarter. Finally, Ikarian Capital LLC purchased a new position in Compass Therapeutics during the fourth quarter worth approximately $4,296,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.